Tiziana Life Sciences

Tiziana Expects To Start Enrolling Patients In Its Phase 2 Clinical Trial To Treat Secondary Progressive Multiple Sclerosis (SPMS) Using Its Novel Intranasal Monoclonal Antibody Foralumab
Sponsored
Tiziana To Announce Six-Month Human Safety And Biomarker Data At The ECTRIMS Annual Congress, Following-Up From Positive Outcomes Data Presented In June
Sponsored
Tiziana Advances Phase 2 Site Selection For Its Lead Clinical Program In Non-Active Secondary Progressive Multiple Sclerosis (SPMS) And The Company Prepares For Six-Month Clinical Data Update
Sponsored
Tiziana To Announce Six-Month Human Safety And Biomarker Data At The ECTRIMS Annual Congress, Following-Up From Positive Outcomes Data Presented In June
Sponsored
Tiziana Advances Phase 2 Site Selection For Its Lead Clinical Program In Non-Active Secondary Progressive Multiple Sclerosis (SPMS) And The Company Prepares For Six-Month Clinical Data Update
Sponsored
Tiziana Life Sciences Prepares To Advance Lead Intranasal Foralumab Program In First-Of-Its-Kind Phase 2a Clinical Trial for Non-Active SPMS Patients
Sponsored
Poised For Growth? This Biotech Is Close To Beginning Key Phase 2a Study With Its Lead Candidate
Sponsored

Tiziana Life Sciences Recent News

As Tiziana Life Sciences (NASDAQ: TLSA) Prepares For Phase 2 Trials, Have They Successfully Derisked Foralumab?
Tiziana Life Sciences, Inc.
Sponsored
Tiziana (NASDAQ: TLSA) Continues The Fight Against Multiple Sclerosis, Will Announce 6-Month Results For Its Novel Treatment Soon
Tiziana Life Sciences (NASDAQ: TLSA), a clinical-stage biotechnology company focused on developing immunotherapies, will soon announce the 6-month results for patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS) receiving its novel intranasal treatment, foralumab. 
Sponsored
Neuroinflammation A Key Indicator For Alzheimer's, But Current Treatments Show Little Success In Reducing Or Even Increase It — Could This Rising Company Have The Answer?
There have been several accelerated approvals granted to treatments for patients with Alzheimer’s disease (AD) by the Food and Drug Administration (FDA) in recent months, and there are several treatments also in development.
Sponsored
Phase 1 Results Are "Extraordinary," Says Chairman Of Scientific Advisory Board As Biomedical Company Preps Phase 2 Trial For MS Treatment
Tiziana Life Sciences (NASDAQ: TSLA) has presented data from its clinical trial showing that five of its six patients with an advanced stage of multiple sclerosis (MS) have shown a reduction in microglia activity,
Sponsored
Publications And Positive Data From Multiple Trials: Six Months In Review For Tiziana Life Sciences (NASDAQ: TLSA)
Tiziana Life Sciences (NASDAQ: TLSA) is a biotechnology company establishing itself in a cutting-edge position in the market with its b
Sponsored
Tiziana Life Sciences (NASDAQ: TLSA) Announces Positive Data In Its Secondary-Progressive Multiple Sclerosis Trial, What Could This Mean For The Company?
Company Moves Ahead With Drug Development
Sponsored
Tiziana's Foralumab Shown To Reduce Microglial Activation In MS Patients; Phase 2a Trial To Begin In Q3 2023
Tiziana Life Sciences Ltd.
Sponsored
Tiziana Life Sciences To Submit Alzheimer's IND In Q2 2023, Seeks $3 Million From An Alzheimer's Foundation To Support Phase 2a Trial
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) announced its plan to submit an IND for intranasal foralumab in patients with mild to moderate Alzheimer’s Disease in Q2 2023.
Sponsored
Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis
Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the clinical stage.
Sponsored
Treatments For Non-Active Secondary Progressive Multiple Sclerosis Remain Scarce – Tiziana Life Sciences' (NASDAQ: TLSA) First-In-Class Foralumab Is Showing Promise
Research is being done into whether there might be treatments that tackle Multiple Sclerosis (MS) through immunosuppression and a reduction of patient neuroinflammation. Anti-CD3 monoclonal antibodies are treatments that seek to reduce inflammation in the body, but all these immunosuppressive drugs use either animal or humanized antibodies, which are less effective than fully human antibodies.
Sponsored
Tiziana Receives Sign-Off From The FDA To Proceed With Phase 2 Clinical Trial In Patients With Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) announced it has received feedback based on the U.S. Food and Drug Administration (FDA) Type C meeting minutes related to the Phase 2 clinical trial of intranasal foralumab in patients with non-active SPMS.
Sponsored